CA2610274A1 - Benzofuran derivatives with therapeutic activities - Google Patents

Benzofuran derivatives with therapeutic activities Download PDF

Info

Publication number
CA2610274A1
CA2610274A1 CA002610274A CA2610274A CA2610274A1 CA 2610274 A1 CA2610274 A1 CA 2610274A1 CA 002610274 A CA002610274 A CA 002610274A CA 2610274 A CA2610274 A CA 2610274A CA 2610274 A1 CA2610274 A1 CA 2610274A1
Authority
CA
Canada
Prior art keywords
dimethylheptyl
hexahydro
dibenzofuran
dimethylpentyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002610274A
Other languages
English (en)
French (fr)
Inventor
Avihai Yacovan
Flavio Grynszpan
Alexander Aizikovich
Marcus Stephen Brody
Avi Bar-Joseph
Sigal Meilin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2610274A1 publication Critical patent/CA2610274A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
CA002610274A 2005-05-31 2006-05-31 Benzofuran derivatives with therapeutic activities Abandoned CA2610274A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68537405P 2005-05-31 2005-05-31
US60/685,374 2005-05-31
PCT/IL2006/000641 WO2006129318A2 (en) 2005-05-31 2006-05-31 Benzofuran derivatives with therapeutic activities

Publications (1)

Publication Number Publication Date
CA2610274A1 true CA2610274A1 (en) 2006-12-07

Family

ID=37039534

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002610274A Abandoned CA2610274A1 (en) 2005-05-31 2006-05-31 Benzofuran derivatives with therapeutic activities

Country Status (9)

Country Link
US (1) US20090054376A1 (cg-RX-API-DMAC10.html)
EP (1) EP1885709A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008542359A (cg-RX-API-DMAC10.html)
KR (1) KR20080019644A (cg-RX-API-DMAC10.html)
CN (1) CN101228146A (cg-RX-API-DMAC10.html)
AU (1) AU2006253734A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0610956A2 (cg-RX-API-DMAC10.html)
CA (1) CA2610274A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006129318A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
CN102300568A (zh) * 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
WO2010091185A2 (en) * 2009-02-05 2010-08-12 Trustees Of Boston College Inhibitors of fructose 1,6-bisphosphatase and methods of use thereof
US8476309B2 (en) 2009-08-20 2013-07-02 The University Of Tennessee Research Foundation Benzofuran cannabinoid compounds and related methods of use
DE102011002934A1 (de) 2011-01-20 2012-07-26 Bayer Schering Pharma Ag CB2 Agonisten zur Behandlung und Vorbeugung der Endometriose
WO2013025984A2 (en) * 2011-08-18 2013-02-21 Temple University Cannabinoid receptor treatments
US9409872B1 (en) * 2015-02-16 2016-08-09 Mark Quang Nguyen Fumarate compounds, pharmaceutical compositions thereof, and methods of use
RU2744758C2 (ru) * 2018-10-19 2021-03-15 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Производные оксимов дибензофуранов, обладающие противосудорожной и нейропротективной активностью
CN109223760B (zh) * 2018-10-31 2021-02-02 广东药科大学 一种苯并呋喃衍生物的用途
CN110251096A (zh) * 2019-05-29 2019-09-20 佛山科学技术学院 一种母猪围产期体温评估方法及系统
RU2747202C2 (ru) * 2019-10-25 2021-04-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство, улучшающее кровоснабжение ишемизированного мозга
EP4161903A4 (en) * 2020-06-04 2024-05-22 London Pharmaceuticals and Research Corporation RIGID CANNABIDIOL ANALOGUES AS STRONG MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF
WO2023075339A1 (ko) * 2021-10-27 2023-05-04 주식회사 휴켐바이오 신규한 트리사이클릭 유도체 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558667A (en) * 1968-11-01 1971-01-26 Sterling Drug Inc Benzofurans from o-phenyl ketoximes
US3931288A (en) * 1972-03-13 1976-01-06 Hoffmann-La Roche Inc. Alkyl esters of 4-chlorophenoxy-4-oxo-cycloalkyl-carboxylic acid
FR2482966A1 (fr) * 1980-05-23 1981-11-27 Cerm Cent Europ Rech Mauvernay 1, 2, 3, 4, 4a, 9b, -hexahydro 4-amino dibenzofurannes, leur procede de preparation et leur application en therapeutique
US4837226A (en) * 1988-04-27 1989-06-06 Warner-Lambert Company Polycyclic amine derivatives useful as cerebrovascular agents
US4960815A (en) * 1988-09-22 1990-10-02 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives

Also Published As

Publication number Publication date
BRPI0610956A2 (pt) 2010-08-03
US20090054376A1 (en) 2009-02-26
WO2006129318A3 (en) 2007-02-08
JP2008542359A (ja) 2008-11-27
EP1885709A2 (en) 2008-02-13
WO2006129318A2 (en) 2006-12-07
KR20080019644A (ko) 2008-03-04
CN101228146A (zh) 2008-07-23
AU2006253734A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
JP7676355B2 (ja) βアドレナリンアゴニストおよびその使用方法
KR20230122083A (ko) 약제학적 활성 화합물로서 칸나비노이드 유도체 및이의 제조 방법
CN107735086A (zh) 大麻油的氢化
US9422235B2 (en) Sulfonamide derivatives with therapeutic indications
US20090054376A1 (en) Benzofuran derivatives with therapeutic activities
TW202120502A (zh) 新穎雜環化合物
JP2005504736A (ja) 新規な二環式及び三環式カンナビノイド
JP5476587B2 (ja) エストロゲン受容体に対して活性を有する縮合化合物
US20230024212A1 (en) Cannabinoid derivatives
Alipour et al. Antinociceptive properties of new coumarin derivatives bearing substituted 3, 4-dihydro-2 H-benzothiazines
JP2010505836A (ja) ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト
KR101739362B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
TWI495640B (zh) 苯並氮呯化合物
Jung et al. Design, synthesis, and discovery of stilbene derivatives based on lithospermic acid B as potent protein tyrosine phosphatase 1B inhibitors
Bourne et al. Novel, potent THC/anandamide (hybrid) analogs
JPH10147585A (ja) 含酸素複素環化合物
JPWO2005079845A1 (ja) 片頭痛予防薬
CN102898284B (zh) 3-烯丙基-[1,1′-联苯]-4-酚及其衍生物以及它们的制备方法和用途
US9120814B2 (en) Compounds with embedded benzopyran motif for core structures and preparation method thereof
WO2007020631A2 (en) Tetracyclic benzofuran derivatives with therapeutic activities
EP1274703A2 (en) N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treament of central nervous system disorders
WO2007018168A1 (ja) アシルグアニジン誘導体またはその塩
KR890000021B1 (ko) 아릴옥시사이클로알칸올 아미노 알킬렌 아릴케톤 및 이의 제조방법
KR20120079274A (ko) 신규한 데구엘린 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약학적 조성물
EP2784077B1 (en) Norepinephrine and selective serotonin receptor blocker and use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued